Xenon Pharmaceuticals Statistics
Total Valuation
XENE has a market cap or net worth of $2.53 billion. The enterprise value is $1.78 billion.
Important Dates
The next estimated earnings date is Thursday, May 8, 2025, after market close.
| Earnings Date | May 8, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
XENE has 76.54 million shares outstanding. The number of shares has increased by 16.45% in one year.
| Current Share Class | 76.54M |
| Shares Outstanding | 76.54M |
| Shares Change (YoY) | +16.45% |
| Shares Change (QoQ) | +0.59% |
| Owned by Insiders (%) | 0.13% |
| Owned by Institutions (%) | 94.22% |
| Float | 70.78M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 3.34 |
| P/TBV Ratio | 3.35 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 17.85, with a Debt / Equity ratio of 0.01.
| Current Ratio | 17.85 |
| Quick Ratio | 17.66 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -27.85% and return on invested capital (ROIC) is -20.50%.
| Return on Equity (ROE) | -27.85% |
| Return on Assets (ROA) | -19.80% |
| Return on Invested Capital (ROIC) | -20.50% |
| Return on Capital Employed (ROCE) | -36.63% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$716,606 |
| Employee Count | 327 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -4.09M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -20.02% in the last 52 weeks. The beta is 1.22, so XENE's price volatility has been higher than the market average.
| Beta (5Y) | 1.22 |
| 52-Week Price Change | -20.02% |
| 50-Day Moving Average | 35.70 |
| 200-Day Moving Average | 39.43 |
| Relative Strength Index (RSI) | 49.07 |
| Average Volume (20 Days) | 825,463 |
Short Selling Information
The latest short interest is 3.95 million, so 5.16% of the outstanding shares have been sold short.
| Short Interest | 3.95M |
| Short Previous Month | 3.64M |
| Short % of Shares Out | 5.16% |
| Short % of Float | 5.58% |
| Short Ratio (days to cover) | 7.82 |
Income Statement
| Revenue | n/a |
| Gross Profit | -210.39M |
| Operating Income | -279.30M |
| Pretax Income | -199.34M |
| Net Income | -234.33M |
| EBITDA | -276.74M |
| EBIT | -279.30M |
| Earnings Per Share (EPS) | -$3.01 |
Full Income StatementBalance Sheet
The company has $626.91 million in cash and $9.02 million in debt, giving a net cash position of $745.39 million or $9.74 per share.
| Cash & Cash Equivalents | 626.91M |
| Total Debt | 9.02M |
| Net Cash | 745.39M |
| Net Cash Per Share | $9.74 |
| Equity (Book Value) | 754.90M |
| Book Value Per Share | 9.88 |
| Working Capital | 599.67M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$181.39 million and capital expenditures -$3.08 million, giving a free cash flow of -$184.46 million.
| Operating Cash Flow | -181.39M |
| Capital Expenditures | -3.08M |
| Free Cash Flow | -184.46M |
| FCF Per Share | -$2.41 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |